Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$22.74 USD
-0.73 (-3.11%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Beam Therapeutics Inc. (BEAM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.75 | $78.00 | $27.00 | 123.18% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Beam Therapeutics Inc. comes to $50.75. The forecasts range from a low of $27.00 to a high of $78.00. The average price target represents an increase of 123.18% from the last closing price of $22.74.
Analyst Price Targets (12)
Broker Rating
Beam Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.93 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.93 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, eight are Strong Buy, representing 53.33% of all recommendations. A month ago, Strong Buy represented 53.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/23/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
3/27/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
2/28/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Hold | Hold |
2/27/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
2/27/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
10/21/2023 | SVB Securities | Mani Foroohar | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.93 |
ABR (Last week) | 1.93 |
# of Recs in ABR | 15 |
Average Target Price | $50.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -1.45 |